A randomized trial finds weekly extended-release buprenorphine yields neonatal outcomes comparable to sublingual treatment.

Please provide your email address to receive an email when new articles are posted on . LOUISVILLE, Ky. — A sublingual film delivered sufficient concentrations of epinephrine to the blood faster than ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Aquestive Therapeutics’ Anaphylm begins to dissolve on ...

LOUISVILLE, Ky. -- A sublingual film may be able to deliver epinephrine as effectively as intramuscular injections and provide an alternate pathway for urgent treatment of allergic anaphylaxis, a ...

Weekly injectable buprenorphine is more effective than daily doses for treating opioid use disorder in pregnancy, with higher ...

Is it possible to train the body to resist seasonal allergies? That’s the hope promised by a new line of immunotherapy ...

Initial placement or subsequent movement of Anaphylm showed no impact on epinephrine pharmacokinetics (PK) or pharmacodynamics (PD), with all results comparable to epinephrine injection Data ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder ...

VANCOUVER, BC / ACCESSWIRE / December 2, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery ...